Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Roberta, Minari"'
Autor:
Silvia La Monica, Federica Vacondio, Kamal Eltayeb, Alessio Lodola, Francesco Volta, Martina Viglioli, Francesca Ferlenghi, Francesca Galvani, Maricla Galetti, Mara Bonelli, Claudia Fumarola, Andrea Cavazzoni, Lisa Flammini, Michela Verzè, Roberta Minari, Pier Giorgio Petronini, Marcello Tiseo, Marco Mor, Roberta Alfieri
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-15 (2024)
Abstract The EGFR tyrosine kinase inhibitor osimertinib has been approved for the first-line treatment of EGFR-mutated Non-Small Cell Lung Cancer (NSCLC) patients. Despite its efficacy, patients develop resistance. Mechanisms of resistance are hetero
Externí odkaz:
https://doaj.org/article/8eb304e906fc460c924afda0b45c67be
Autor:
Roberta Minari, PhD, Samuel Valentini, MSc, Denise Madeddu, PhD, Andrea Cavazzoni, PhD, Silvia La Monica, PhD, Costanza Anna Maria Lagrasta, MSc, Roberto Bertorelli, MSc, Veronica De Sanctis, PhD, Paola Fassan, MSc, Cinzia Azzoni, PhD, Lorena Bottarelli, PhD, Caterina Frati, PhD, Letizia Gnetti, MD, Francesco Facchinetti, MD, Pier Giorgio Petronini, PhD, Roberta Alfieri, PhD, Alessandro Romanel, PhD, Marcello Tiseo, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 2, Pp 100278- (2022)
Introduction: ALK tyrosine kinase inhibitors (TKIs) are the standard treatment for advanced ALK-positive NSCLC. Nevertheless, drug resistance inevitably occurs. Here, we report a case of a patient with metastatic ALK-positive lung adenocarcinoma with
Externí odkaz:
https://doaj.org/article/e7a0f0aaa4584907a17791252608959c
Autor:
Silvia La Monica, Roberta Minari, Daniele Cretella, Lisa Flammini, Claudia Fumarola, Mara Bonelli, Andrea Cavazzoni, Graziana Digiacomo, Maricla Galetti, Denise Madeddu, Angela Falco, Costanza Annamaria Lagrasta, Anna Squadrilli, Elisabetta Barocelli, Alessandro Romanel, Federico Quaini, Pier Giorgio Petronini, Marcello Tiseo, Roberta Alfieri
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 38, Iss 1, Pp 1-12 (2019)
Abstract Background The third generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) osimertinib has been initially approved for T790M positive Non-Small Cell Lung Cancer (NSCLC) and more recently for first-line treatment
Externí odkaz:
https://doaj.org/article/0332689cda2e4440a52ebd48a300166b
Autor:
Ingrid Garajová, Andrea Cavazzoni, Michela Verze, Roberta Minari, Giuseppe Pedrazzi, Rita Balsano, Fabio Gelsomino, Raffaele Dalla Valle, Graziana Digiacomo, Elisa Giovannetti, Francesco Leonardi
Publikováno v:
Life, Vol 12, Iss 7, p 960 (2022)
Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly devastating disease with rising incidence and poor prognosis. The lack of reliable prognostic biomarkers hampers the individual evaluation of the survival and recurrence potential. Metho
Externí odkaz:
https://doaj.org/article/26ee6fb0eea9480ca336f2d9c103f38b
Autor:
Alessandro Leonetti, Roberta Minari, Giulia Mazzaschi, Letizia Gnetti, Silvia La Monica, Roberta Alfieri, Nicoletta Campanini, Michela Verzè, Andrea Olivani, Luigi Ventura, Marcello Tiseo
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Introduction: Small cell lung cancer (SCLC) transformation represents a mechanism of resistance to osimertinib in EGFR-mutated lung adenocarcinoma, which dramatically impacts patients' prognosis due to high refractoriness to conventional treatments.C
Externí odkaz:
https://doaj.org/article/b1f8f75a6ce348e197abf27fa2247afe
Autor:
Michela Verzè, Monica Pluchino, Alessandro Leonetti, Matilde Corianò, Francesco Bonatti, Maria P. Armillotta, Fabiana Perrone, Miriam Casali, Roberta Minari, Marcello Tiseo
Publikováno v:
Translational Lung Cancer Research. 11:2588-2600
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::caa4a72255b9dc9401e0749c9e1cb888
https://doi.org/10.21037/tlcr-22-390
https://doi.org/10.21037/tlcr-22-390
Autor:
Giulia Mazzaschi, Gianluca Milanese, Paolo Pagano, Denise Madeddu, Letizia Gnetti, Francesca Trentini, Angela Falco, Caterina Frati, Bruno Lorusso, Costanza Lagrasta, Roberta Minari, Luca Ampollini, Mario Silva, Nicola Sverzellati, Federico Quaini, Giovanni Roti, Marcello Tiseo
Publikováno v:
Data in Brief, Vol 31, Iss , Pp 105781- (2020)
The immune regulation of cancer growth and regression has been underscored by the recent success of immunotherapy. The possibility that immune microenvironmental factors may impact on clinical outcome and treatment response still requires intense inv
Externí odkaz:
https://doaj.org/article/372c541341f747979dbd6d318d5721e8
Autor:
Silvia La Monica, Daniele Cretella, Mara Bonelli, Claudia Fumarola, Andrea Cavazzoni, Graziana Digiacomo, Lisa Flammini, Elisabetta Barocelli, Roberta Minari, Nadia Naldi, Pier Giorgio Petronini, Marcello Tiseo, Roberta Alfieri
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 36, Iss 1, Pp 1-12 (2017)
Abstract Background Osimertinib is a third-generation EGFR-TKI with a high selective potency against T790M-mutant NSCLC patients. Considering that osimertinib can lead to enhanced HER-2 expression on cell surface and HER-2 overexpression is a mechani
Externí odkaz:
https://doaj.org/article/68e6e65fc31949e1aecda172a0c9b042
Autor:
Giulia Mazzaschi, Fabiana Perrone, Roberta Minari, Michela Verzè, Cinzia Azzoni, Lorena Bottarelli, Monica Pluchino, Maria Pia Armillotta, Annalisa Ubaldi, Annalisa Altimari, Elisa Gruppioni, Francesca Sperandi, Elisa Andrini, Giorgia Guaitoli, Stefania Bettelli, Lucia Longo, Federica Bertolini, Fausto Barbieri, Maria Pagano, Candida Bonelli, Elena Tagliavini, Davide Nicoli, Alessandro Ubiali, Adriano Zangrandi, Serena Trubini, Manuela Proietto, Letizia Gnetti, Marcello Tiseo
Publikováno v:
Clinical Lung Cancer. 23:e478-e488
Targeting Kirsten Rat Sarcoma (KRAS) has been deemed impossible for long time, but new drugs have recently demonstrated promising results. Evidence on the outcome of KRAS-mutant advanced-NSCLC treated with new standard regimens are still scarce. Thus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7053999a8fa97bfc0f7fa4b0494b6c82
https://doi.org/10.1016/j.cllc.2022.07.005
https://doi.org/10.1016/j.cllc.2022.07.005
Autor:
Alessandro Leonetti, Mjriam Capula, Roberta Minari, Giulia Mazzaschi, Alessandro Gregori, Btissame El Hassouni, Filippo Papini, Paola Bordi, Michela Verzè, Amir Avan, Marcello Tiseo, Elisa Giovannetti
Publikováno v:
Cells, Vol 10, Iss 6, p 1520 (2021)
Background: Resistance to EGFR-TKIs constitutes a major challenge for the management of EGFR-mutated NSCLC, and recent evidence suggests that deregulation of specific microRNAs (miRNAs) may influence resistance to targeted agents. In this retrospecti
Externí odkaz:
https://doaj.org/article/7a23652a75214cf3b35b2928e633ea77